SCHEMBL25899174

SCHEMBL25899174

CC(C)c1cc2c(=O)nc(N)[nH]c2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.38
SLC2A1 P11166 1/20 0.38
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP3A4 P08684 1/20 0.35
BLM P54132 1/20 0.35
CYP1A2 P05177 1/20 0.34
TRPV1 Q8NER1 1/20 0.34
XDH P47989 3/20 0.33
BACE1 P56817 1/20 0.33
TYMS P04818 2/20 0.31
QTRT1 Q9BXR0 1/20 0.31
PNP P00491 1/20 0.31
DAO P14920 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
DYRK1A Q13627 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24629146 0.77 CYP3A4 (0.42) CYP3A4BLMCYP1A2XDHBACE1
SCHEMBL24538722 0.73 PNP (0.38) DHFRSLC2A1MEN1ALDH1A1KMT2A
SCHEMBL12192591 0.73 CYP3A4 (0.41) DHFRSLC2A1MEN1ALDH1A1KMT2A
SCHEMBL31231913 0.67 CYP3A4 (0.57) MEN1ALDH1A1KMT2ACYP3A4BLM
SCHEMBL19757295 0.67 KIF11 (0.38) DHFRMEN1ALDH1A1KMT2ATRPV1
SCHEMBL24500022 0.67 PNP (0.43) MEN1ALDH1A1KMT2ATRPV1TYMS
SCHEMBL25899207 0.67 GART (0.45) XDH
SCHEMBL9044197 0.65 DYRK1A (0.53) CYP3A4BLMXDHBACE1TYMS
SCHEMBL8531415 0.62 KDM5B (0.33) DHFRALDH1A1CYP3A4BLMCYP1A2
SCHEMBL18363786 0.61 KIF11 (0.38) ALDH1A1DAODYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-09-07 US disclosed
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, FCGR3B, FCGR2A DHFR 2599/4885SLC2A1 2101/4885MEN1 1824/4885
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, ASGR1, FCGR3B DHFR 4085/4885SLC2A1 1778/4885MEN1 2803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.